Loading clinical trials...
Loading clinical trials...
Pilot Phase 1 Study of Perioperative Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic, WHO Grade 1 or 2, SSTR Positive, Gastroenteropancreatic Neuroendocrine Tumors Who Are Candidates for Cytoreductive Surgery
Conditions
Interventions
Lutathera
Gallium 68 Dotatate
+3 more
Locations
1
United States
Stanford Cancer Institute Palo Alto
Stanford, California, United States
Start Date
March 17, 2021
Primary Completion Date
July 1, 2026
Completion Date
September 1, 2027
Last Updated
September 9, 2025
NCT05636618
NCT06790706
NCT04727723
NCT05262556
NCT05987176
NCT01842165
gitrialeligibility@stanford.edu gitrialeligibility@stanford.edu
CONTACT
(650) 498-7757gpineda@stanford.edugitrialeligibility@stanford.edu gitrialeligibility@stanford.edu
CONTACT
(650) 498-7757gitrialeligibility@stanford.eduLead Sponsor
Stanford University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions